Bicalutamide (|[lsquo]|Casodex|[rsquo]|) 150|[thinsp]|mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1|[thinsp]|y) in the early prostate cancer programme

摘要

Trial 24 is one of three placebo-controlled trials within the ongoing bicalutamide ('Casodex'?) Early Prostate Cancer (EPC) programme evaluating bicalutamide 150mg/day in addition to radical prostatectomy, radiotherapy or watchful waiting for T1b–4, any N, M0 prostate cancer. In Trial 24, at 5.1y median follow-up, the addition of bicalutamide significantly (PP=0.746). In the context of the whole EPC programme, long-term bicalutamide is not appropriate for localised disease, yet provides advantages in delaying disease progression in patients with locally advanced prostate cancer.